Carlisle Companies News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

04.12.17	CSL Behring Advances to Phase 3 Cardiovascular Outcomes Trial for CSL112, its Novel Apolipoprotein A-I (Human) Infusion Therapy (PR Newswire)
16.11.17	SQI Diagnostics Reports Fourth Quarter and Fiscal 2017 Results (PR Newswire)
13.11.17	Carlisle Companies Incorporated -- Moody's affirms Carlisle Companies' Baa2 senior unsecured rating; assigns Baa2 senior unsecured rating to proposed notes issuance (Moodys)
09.11.17	Lancet Neurology Publishes Results from CSL Behring Phase III Study of Hizentra® (Immune Globulin Subcutaneous [Human] 20% liquid) as Maintenance Therapy in Patients with Chronic Inflammatory... (PR Newswire)
29.10.17	Data on the Preventive Effects of HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) in Subjects with Very Frequent HAE Attacks Presented by CSL Behring at the 2017 ACAAI Annual Scientific Meeting (PR Newswire)
24.10.17	Carlisle Companies Inc. Q3 Earnings Decline 24% (RTTNews)
24.10.17	New Data for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) to be presented at the 2017 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting (PR Newswire)
12.10.17	CSL Behring Trains Employees to Save Lives in Their Communities and Workplace with CPR; AHA Encourages Other Businesses to Do the Same (PR Newswire)
02.10.17	Carlisle To Acquire Accella For $670 Mln - Quick Facts (RTTNews)
02.10.17	Arsenal Announces Sale of Accella Performance Materials to Carlisle Companies (PR Newswire)
28.09.17	Japan's Ministry of Health, Labour and Welfare Approves AFSTYLA® - CSL Behring's Novel Recombinant Haemophilia A Treatment (PR Newswire)
26.09.17	Avis aux médias - Le ministre célèbre le 150e anniversaire du Canada à la Ferme expérimentale centrale (PR Newswire)
26.09.17	AVIS - Le CN divulguera ses résultats financiers et d'exploitation du troisième trimestre de 2017 le 24 octobre 2017 (PR Newswire)
22.09.17	Avis aux médias : Annonce en matière d'infrastructure en Alberta (PR Newswire)
22.09.17	Moody's upgrades perspective to stable and confirms Ecopetrol S.A.'s investment-grade rating (PR Newswire)
19.09.17	CSL Behring Will Help Transform Biotech Education and Research with $4.92 Million Gift to Penn State (PR Newswire)
15.09.17	CSL Behring Announces FDA Approval of Privigen® [Immune Globulin Intravenous (Human), 10% Liquid] for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Adults (PR Newswire)
14.09.17	CSL Behring Joins Together With Conference Attendees to Make Donation to IPOPI (PR Newswire)
08.09.17	Design and Construction Amnesia: Liberty Building Forensics Group Says, "We Have Lost our Minds and it is Causing Catastrophic Mold and Moisture Building Failures." (PR Newswire)
08.09.17	Initiating Research Reports on Rubber & Plastics Equities -- Goodyear Tire & Rubber, Carlisle, Cooper Tire & Rubber, and Trinseo (PR Newswire)
01.09.17	SJ Strategic Investments, LLC, Gracetree Investments, LLC, Gregory Asset Partners, LLC and the Gregory Irrevocable Equalizing Trust, acting jointly Files Early Warning Report (PR Newswire)
28.08.17	CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform (PR Newswire)
22.08.17	Clutch Announces Top Agencies and Developers in Philadelphia and Atlanta (PR Newswire)
25.07.17	Carlisle Companies Inc. Profit Drops 11% In Q2 (RTTNews)
25.07.17	HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) Now Available in the United States for Patients with Hereditary Angioedema (PR Newswire)
21.07.17	CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) (PR Newswire)
19.07.17	FDA Accepts CSL Behring's Supplemental Biologics License Application for Hizentra® Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Indication (PR Newswire)
12.07.17	New Data Demonstrate Prophylactic Treatment with IDELVION® Reduces Bleed Frequency and Has Potential to Positively Impact Patients with Haemophilia B (PR Newswire)
11.07.17	CSL Behring Awards Researchers to Advance Immunoglobulin Therapy in Treating Neurological Disorders (PR Newswire)
10.07.17	New Findings Show AFSTYLA® Provides Long-lasting Efficacy without Increased Product Consumption for Prophylactic and On-Demand Treatment of Haemophilia A (PR Newswire)
06.07.17	New Data for Two Leading Haemophilia Medicines -- AFSTYLA® and IDELVION® -- to be Presented at the International Society on Thrombosis and Haemostasis Congress 2017 (PR Newswire)
30.06.17	How These Rubber and Plastics Stocks are Performing? -- Goodyear Tire & Rubber, Carlisle, Cooper Tire & Rubber, and Trinseo (PR Newswire)
23.06.17	FDA Approves HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), First and Only Subcutaneous Preventive Treatment for Hereditary Angioedema (PR Newswire)
13.06.17	CSL to acquire majority stake in Chinese plasma fractionator Wuhan Zhong Yuan Rui De Biologicals Products (PR Newswire)
19.05.17	New Innovation in the Fight Against Hemophilia Earns CSL Behring the NORD 2017 Industry Innovation Award (PR Newswire)
28.04.17	Carlisle Companies Inc. Q1 Income Declines 10% (RTTNews)
25.04.17	Wirecard North America and CSL Plasma Launch First Cash-Back Donor Prepaid Card (PR Newswire)
25.04.17	Wirecard North America and CSL Plasma Launch First Cash-Back Donor Prepaid Card (PR Newswire)
19.04.17	Therapeutic Goods Administration Approves AFSTYLA® - CSL Behring's Novel Recombinant Haemophilia A Treatment (PR Newswire)
10.04.17	Improving Access to Lifesaving Treatments for Bleeding Disorders in the Developing World (PR Newswire)
07.04.17	Technical Reports on Consumer Goods Equities -- Travelport, Liberty TripAdvisor, Brunswick, and Carlisle (PR Newswire)
31.03.17	Jeffrey Modell Foundation to Open the First North African Network for Primary Immunodeficiencies (PR Newswire)
29.03.17	CSL Behring Awards Grant To Patient Groups To Develop Innovative Ways To Advocate For Patients (PR Newswire)
29.03.17	/DISREGARD RELEASE: CSL Behring/ (PR Newswire)
22.03.17	New England Journal of Medicine Publishes Pivotal Phase III Data for CSL Behring's Subcutaneous C1-Esterase Inhibitor in HAE Patients (PR Newswire)
01.03.17	Largest Ever CIDP Clinical Study Completed (PR Newswire)
15.02.17	Carlisle Companies Names Robert Roche VP And CFO (RTTNews)
14.02.17	FDA Accepts CSL Behring's Biologics License Application Supplement for Using Privigen® to Treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a Rare Neurological Condition (PR Newswire)
09.02.17	Carlisle Companies Inc. Q4 Income Rises 6% (RTTNews)
02.12.16	The Lancet Respiratory Medicine Publishes RAPID Extension Study Data on Effect of Zemaira® [Alpha1-Proteinase Inhibitor (Human)] in Patients with Alpha-1 Antitrypsin Deficiency (AATD) (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Carlisle Companies Inc.

Aktien Top/Flop

Meistgelesene Nachrichten